It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Explore our rapid model of glucocorticoid-induced insulin resistance, ideal for testing antidiabetic potential of new drugs. Witness the inhibitory effects of mifepristone and CORT125134 on insulin resistance and hyperglycaemia in rats.
Explore our ready-to-use Dietary-Induced Obese (DIO) mouse and rat models, perfect for assessing weight loss interventions and testing novel treatments. Our DIO mouse model boasts stable weight, significant adiposity, insulin resistance, lipid deposition, and elevated plasma lipids. Experience proven predictive validity in a 4-week study, showcasing the effectiveness of semaglutide. Additionally, our DIO rat model, replicating a calorie-dense Western diet, offers excellent predictive validity with on-demand production in just 16 weeks.
Explore In Vivo Pharmacokinetic (PK) Studies: Learn about drug absorption, distribution, metabolism, and elimination (ADME). Discover the key parameters – AUC, Cmax, t½, Vss, and clearance – in early-stage drug development. Uncover insights into oral bioavailability and first-pass hepatic elimination. Enhance your understanding of PK through detailed ADME analysis and renal/biliary clearance studies.
Discover the importance of aqueous solubility in drug discovery and development. Overcome low solubility obstacles with our kinetic and thermodynamic solubility assays. Improve drug absorption and formulation. Explore our DMPK/ADME capabilities now!
Drug Metabolism Insights: Explore Metabolite Profiling with Sygnature Discovery. Discover how liver metabolism influences drug clearance, and how Sygnature’s specialized assays, utilizing hepatocytes, microsomes, and more, can guide your drug discovery project. Predict in vivo hepatic clearance, identify key metabolic pathways, and optimise administration strategies for enhanced therapeutic outcomes.
Learn about the impact of drug binding to red blood cells (RBC) and plasma proteins on pharmacokinetics. Discover how RBC binding can affect drug concentration, pharmacological action, and potential toxicity. Understand the importance of early assessment during drug discovery.
Enhance drug development using PAMPA assay for permeability assessment. Rapid, accurate, and high-throughput method. Sygnature’s advanced approach with Corning’s pre-coated plate system. LC-MS/MS readouts and precise calibration curve ensure reliable results. Caffeine and Famotidine controls included.
